Novo Invests $507 Million on Wegovy Pill Plant in Ireland
The Wegovy pill is a key part of Novo’s battle to remain competitive in the weight-loss market it once dominated.
Photographer: George Frey/BloombergNovo Nordisk A/S will spend €432 million ($507 million) upgrading an Irish factory to produce its hit Wegovy weight-loss pill for markets outside the US.
The facility which employs 260 staff will provide “significant” additional capacity for current and future obesity and diabetes medicines, the Danish pharmaceutical company said in a statement.